On Topic Virtual Roundtable: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer

Release Date:
October 7, 2021
Expiration Date: October 6, 2022

Target Audience
The target audience for this activity is community and academic medical oncologists,
gynecologic oncologists, surgical oncologists, obstetricians and gynecologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with ovarian cancer.

Learning Objectives
After participating in this activity, participants should be better able to:

  • Select genetic testing for patients with newly diagnosed advanced ovarian cancer 
  • Utilize clinical features and genetic information to plan treatment for patients with newly diagnosed advanced ovarian cancer 
  • Compare and contrast current and emerging treatment strategies for patients with newly diagnosed ovarian cancer 
  • Manage adverse events associated with maintenance therapy for patients with newly diagnosed advanced ovarian cancer

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Robert Coleman, MD, FACS, FACOG
Chief Scientific Officer
Texas Oncology - US Oncology Research
Houston, Texas

Consultant /Advisory Board: Deciphera, Agenus, Gradalis, Alkermes, Epsilogen, Karyopharm, Merck, GSK, Seagen, Slovis, Novocure, DNAMx, AstraZeneca, Genelux, Genentech/Roche, Abbvie, OncXerna
Research Funding: Merck, Abbvie, Astrazeneca, Seagen, Genentech/Roche

Angela Alvarez Secord, MD

Professor of Obstetrics and Gynecology
Duke Cancer Institute
Durham, North Carolina

Consulting Fees/Advisory Board: Myriad, AbbVie, Aravive, AstraZeneca, Eisai,Tesaro/GSK and Regeneron
Research Funding: AbbVie,Astra Zeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep Ltd, Merck, Oncoquest, PharmaMar, Roche/Genentech, Seagen Inc, Tesaro/GSK, VBL Therapeutics and National Cancer Trial Network

Paula Anastasia, RN, MN, AOCN
GYN-Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, California

Consulting Fees: Merck
Speakers Bureau: Genentech

Patient Advocate & Ovarian Cancer Survivor
Kathy Jennings

No relevant financial relationships to disclose

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This activity is supported by independent educational grants from AstraZeneca and Merck.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.